Yes, chewing tobacco causes inflammation, both in the mouth where the tobacco sits and throughout the body. Smokeless tobacco users have roughly four times higher levels of C-reactive protein (a key blood marker of inflammation) compared to non-users. The inflammation stems from multiple overlapping sources: direct chemical irritation of oral tissue, nicotine’s effects on immune cells, shifts in mouth bacteria, and oxidative damage to cells.
How Chewing Tobacco Inflames Oral Tissue
The most direct pathway is simple: holding a wad of tobacco against your cheek or gums exposes that tissue to a concentrated mix of irritants. Smokeless tobacco products are formulated with alkaline additives that raise pH, which helps your body absorb nicotine faster but also causes localized chemical burns to the delicate lining of your mouth. This triggers your immune system’s standard damage response, sending white blood cells to the area and releasing signaling molecules that drive inflammation.
Studies measuring saliva in smokeless tobacco users find elevated levels of several inflammatory signaling molecules, including IL-1, IL-6, IL-8, and TNF-alpha. These are the chemical messengers your immune cells produce when they detect tissue damage or foreign substances. In one study comparing different tobacco products, snus users had the highest concentrations of all these markers, and those elevated levels tracked closely with visible changes to the oral lining.
At the cellular level, nicotine itself amplifies the problem. When gum tissue cells are exposed to nicotine in lab studies, they produce more IL-1 and IL-6 on their own. Worse, there’s a synergistic effect: when nicotine combines with bacterial toxins already present in the mouth, the inflammatory response is greater than either would cause alone. Nicotine also disrupts connective tissue by reducing collagen production and increasing the enzymes that break collagen down, weakening the structural foundation of your gums.
Changes to Mouth Bacteria
Chewing tobacco reshapes the bacterial community in your mouth in ways that fuel more inflammation. The tobacco creates a low-oxygen, acidic environment that favors anaerobic bacteria, the types that thrive without oxygen. Species like Fusobacteria, Prevotella, and Porphyromonas gingivalis become more abundant. These aren’t just passive bystanders. Their cell walls contain molecules that activate specific inflammatory receptors on your immune cells, triggering a cascade of pro-inflammatory signaling.
This bacterial shift also promotes periodontal disease. The anaerobic species enriched by tobacco use are the same ones implicated in gum infections and bone loss around teeth. Fusobacteria, which are particularly abundant in smokeless tobacco users, are opportunistic pathogens that have been linked not only to oral disease but also to colorectal cancer, where they appear to promote tumor growth by stoking chronic inflammation.
Systemic Inflammation Beyond the Mouth
The inflammation from chewing tobacco isn’t confined to your gums. A cross-sectional study of 400 people found that smokeless tobacco users had a mean C-reactive protein level of 0.77 mg/dL, compared to 0.18 mg/dL in non-users. Their erythrocyte sedimentation rate, another blood marker of inflammation, was also significantly elevated (median of 15 versus 10 in non-users).
That said, the systemic inflammatory effect is smaller than what cigarette smoking produces. A large analysis published in Circulation found that current cigarette smokers had 29% higher levels of high-sensitivity CRP compared to never-smokers, while current smokeless tobacco users had 11% higher levels. Cigarette smoking also raised IL-6 by 28%, but smokeless tobacco showed no statistically significant association with IL-6 in the blood. So chewing tobacco does raise whole-body inflammation, just not as dramatically as smoking does.
Oxidative Stress and Cell Damage
Chewing tobacco also generates oxidative stress, a form of cellular damage that goes hand in hand with inflammation. Nicotine disrupts the balance between harmful reactive molecules and your body’s antioxidant defenses. In one study of smokeless tobacco users, red blood cell levels of malondialdehyde (a byproduct of oxidative damage to fats in cell membranes) were significantly higher than in non-users: 0.229 versus 0.197. At the same time, two key antioxidant enzymes, superoxide dismutase and catalase, were significantly reduced.
This means chewing tobacco both increases the production of damaging molecules and reduces your body’s ability to neutralize them. The resulting oxidative stress feeds back into the inflammatory cycle, as damaged cells release signals that recruit more immune activity.
From Inflammation to Precancerous Lesions
Chronic, repetitive inflammation in the mouth creates the conditions for potentially dangerous tissue changes. The most common is smokeless tobacco keratosis, a white or gray patch that forms where the tobacco habitually sits. This results from ongoing irritation and is unique to smokeless tobacco users. Beyond keratosis, users develop leukoplakia at higher rates, and more than 33% of oral cancers are preceded by leukoplakia.
The progression follows a recognizable pattern. Persistent irritation leads to chronic inflammation, which leads to abnormal cell growth. Erythroplakia (red patches) and erythroleukoplakia (mixed red and white patches) carry even higher risk than leukoplakia alone, with most biopsied cases showing dysplasia or carcinoma in situ. In cases that progress to verrucous carcinoma or squamous cell carcinoma, intense inflammatory cell buildup in the tissue beneath the lesion is a consistent finding. The inflammation isn’t just a bystander; it’s part of the environment that allows abnormal cells to take hold.
Cardiovascular Effects
Nicotine from chewing tobacco impairs blood vessel function, specifically reducing the ability of arteries to dilate properly in response to blood flow. This endothelial dysfunction is a recognized early marker of cardiovascular risk. However, the picture is more nuanced than with smoking. A 2024 American Heart Association policy statement noted that biomarker studies in the U.S. found no clear association between smokeless tobacco use and standard cardiovascular harm markers, and Swedish research found no evidence of accelerated plaque buildup in the arteries of smokeless tobacco users.
The current understanding is that smokeless tobacco doesn’t appear to speed up atherosclerosis the way cigarettes do, but it is associated with worse outcomes in people who already have heart disease or cerebrovascular disease. The acute effects of nicotine on blood pressure, heart rate, and arterial stiffness are real, even if they don’t translate into the same long-term vascular damage that combustible tobacco causes.
How Long Inflammation Lasts After Quitting
Most research on post-cessation recovery comes from smoking studies, but the inflammatory markers involved are the same ones elevated in smokeless tobacco users. C-reactive protein levels return to never-user levels roughly one year after quitting. White blood cell counts take longer, remaining elevated for up to 10 years before normalizing. The oral changes specific to chewing tobacco, like smokeless tobacco keratosis, often begin resolving within weeks of stopping, though the timeline depends on how long and how heavily you used.
The recovery data reinforces something important: the inflammation caused by chewing tobacco is not permanent. Your body’s inflammatory markers do return to baseline, and the earlier you stop, the sooner that process begins.